The KYMRIAH Experience
|
|
- Louise Goodman
- 6 years ago
- Views:
Transcription
1 The KYMRIAH Experience INDICATION KYMRIAH (tisagenlecleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. IMPORTANT SAFETY INFORMATION FOR KYMRIAH WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL TOXICITIES Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab. Neurological toxicities, which may be severe or life-threatening, can occur following treatment with KYMRIAH, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIAH. Provide supportive care as needed. KYMRIAH is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS. Please see full Prescribing Information for KYMRIAH, including
2 THE LEADER IN CAR-T CELL THERAPY Novartis is proud to offer KYMRIAH (tisagenlecleucel), the first chimeric antigen receptor T-cell (CAR-T cell) therapy approved by the US Food and Drug Administration (FDA). To deliver on our commitment to patients, Novartis has designed a flexible and integrated KYMRIAH manufacturing supply chain platform that allows for a high-quality, individualized treatment approach. Our proven process includes cryopreservation of leukapheresis material and reprogramming T cells with the only FDA-approved 4-1BB CAR. Contraindications None Warnings and Precautions Cytokine Release Syndrome: CRS, including fatal or life-threatening reactions, occurred following treatment with KYMRIAH. In Study 1, CRS occurred in 79% (54/68) of patients receiving KYMRIAH, including grade 3 or 4 (Penn grading system) CRS in 49% (33/68) of patients. The median time to onset of CRS was 3 days (range: 1-22 days). Of the 54 patients with CRS, 27 (50%) received tocilizumab; 7 (13%) patients received 2 doses of tocilizumab, 3 (6%) patients received 3 doses of tocilizumab and 14 (26%) patients received addition of corticosteroids (e.g. methylprednisolone). The median time to resolution of CRS was 8 days (range: 1-36 days).
3 THE LEADER IN CAR-T CELL THERAPY Since 2011, Novartis has manufactured KYMRIAH (tisagenlecleucel) CAR-T cells for more than 300 patients, from 11 countries, across various indications in both clinical trials and the commercial setting. With this experience, we have continuously made enhancements to increase capacity in our 173,000-ft 2, FDA-inspected and audited manufacturing facility. Through our efforts, we have demonstrated a high-quality, reproducible product and strive to reduce turnaround time to meet the needs of patients. Cytokine Release Syndrome (continued): Key manifestations of CRS may include high fever, lower than normal blood pressure, difficulty breathing, and may be associated with hepatic, renal, and cardiac dysfunction, and coagulopathy. Risk factors for severe CRS are high pre-infusion tumor burden, uncontrolled or accelerating tumor burden following lymphodepleting chemotherapy, active infections, and/or inflammatory processes. Delay KYMRIAH infusion after lymphodepleting chemotherapy if patient has unresolved serious adverse reactions from preceding chemotherapies, active uncontrolled infection, active graft vs host disease, or worsening of leukemia burden.
4 OUR MANUFACTURING DIFFERENCE KYMRIAH (tisagenlecleucel) is manufactured for each individual patient, using their own cells, at the Novartis Manufacturing Facility in Morris Plains, NJ, a 30-minute drive from Newark Liberty International Airport. Novartis has enhanced our manufacturing capacity to meet the needs of patients with a target turnaround time of 22 days from receipt* to return. Because KYMRIAH is an individualized therapy, Novartis has developed a process with rigorous quality control to ensure that the Chain of Identity is maintained throughout the manufacturing process. At every step of the process, from leukapheresis to infusion, patient identity must b confirmed and product labels verified for accuracy and patient safety. * Receipt of both leukapheresis material and hospital purchase order for KYMRIAH. Target based on receipt of leukapheresis material that meet required specifications. Cytokine Release Syndrome (continued): Ensure tocilizumab is available on-site prior to KYMRIAH infusion. Monitor patients for signs or symptoms of CRS for at least 4 weeks after treatment. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur. At the first sign of CRS, immediately evaluate the patient for hospitalization and institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated.
5 OUR MANUFACTURING DIFFERENCE COLLECTION AND CRYOPRESERVATION SHIP LEUKAPHERESIS PRODUCT RECEIVED RECEIPT TO RETURN TARGET: 22 DAYS SHIP TO CENTER MANUFACTURING STARTS (REPROGRAMMING) CRYOPRESERVATION QUALITY RELEASE (INCLUDES STERILITY RESULTS) 1 day 10 to 11 days 9 days 1 day Neurological Toxicities: Neurological toxicities, which may be severe or life-threatening, can occur following treatment with KYMRIAH (tisagenlecleucel). The majority of neurological toxicities occurred within 8 weeks following KYMRIAH infusion. In Study 1, neurological toxicities within 8 weeks after KYMRIAH infusion occurred in 65% of patients, including grade 3 or 4 neurological toxicities in 18% of patients, and 75% of events resolved within 12 days. The most common neurological toxicities were headache (37%), encephalopathy (34%), delirium (21%), anxiety (13%), and tremor (9%).
6 THE KYMRIAH PROCESS Collection and Cryopreservation After an appropriate patient is identified for treatment with KYMRIAH (tisagenlecleucel), some of their white blood cells, including T cells, are collected through leukapheresis. The fresh leukapheresis material is then preserved at the treatment center s cellprocessing facility within 24 hours of collection. This is known as cryopreservation. Cryopreservation does not impair T-cell viability or function. 1-3 Researched and refined over more than 4 decades, cryopreservation has become an essential component of protocols for cell therapies, including CAR-T cell therapy. 1,3,4 Neurological Toxicities (continued): Other manifestations of neurological toxicities included disturbances in consciousness, disorientation, confusion, agitation, seizures, mutism and aphasia. Monitor patients for neurological events and exclude other causes for symptoms. Provide supportive care as needed for KYMRIAH-associated neurological events.
7 WHY CRYOPRESERVE? Cryopreservation allows for greater flexibility Adaptable Apheresis You can schedule collection as soon as a patient is identified, as you do not need to wait for a manufacturing slot. Storage You can proactively collect cells, and store leukapheresis material for up to 9 months before manufacturing begins, if you decide that is the best treatment course for your patient. 5 Cryopreserved Shipping When the cryopreserved leukapheresis material is shipped to our state-of-the-art manufacturing facility, the shipping container provides a 1-week safety net to keep cryopreserved leukapheresis material frozen in case of weather-related delays. KYMRIAH REMS to Mitigate CRS and Neurological Toxicities: Because of the risk of CRS and neurological toxicities, KYMRIAH (tisagenlecleucel) is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS. Further information is available at or KYMRIAH ( ). Hypersensitivity Reactions: Allergic reactions may occur with KYMRIAH. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide or dextran 40 in KYMRIAH.
8 THE ONLY FDA-APPROVED 4-1BB CAR-T CELL THERAPY Our proven process includes reprogramming a patient s own T cells into KYMRIAH (tisagenlecleucel), using a CAR containing a 4-1BB costimulatory domain. 6 Once the cryopreserved leukapheresis material is received at our state-of-the-art manufacturing facility, it is thawed and reprogramming can begin. Lentiviral vector Reprogrammed KYMRIAH CAR-T cell Detailed view of cell interaction Cell membrane 4-1BB: enhances expansion and persistence CD3ζ: critical signaling domain for activation and antitumor activity Lentiviral transduction delivers transgene encoding the CD19-specific CAR KYMRIAH CAR 6 KYMRIAH CAR-T cells have the ability to bind to and eliminate CD19-expressing cancerous and other B cells 6,7 Serious Infections: Serious infections, including life-threatening or fatal infections, occurred in patients after KYMRIAH infusion. In Study 1, infections (all grades) after KYMRIAH infusion occurred in 40 patients (59%), including 24 patients (35%) with grade 3 and 4 infections and 2 patients (3%) with fatal infections. Infections with an unknown pathogen occurred in 41% of patients, viral infections in 26%, bacterial infections in 19%, and fungal infections in 13%.
9 EXPANSION AND ENDURANCE Costimulatory domains vary by CARs, and play a critical role in augmenting CAR-T cell functions of expansion and endurance. 4-1BB CD28 Used in KYMRIAH Shown to enhance early expansion and long-term endurance of CAR-T cells in vivo and in vitro 7,8 Demonstrated to induce central memory T-cell differentiation for enduring protection and immunosurveillance in vitro 8 May help KYMRIAH (tisagenlecleucel) CAR-T cells evade some of the body s native immunosuppressive stimuli 9 Shown to be involved in early and rapid expansion in vitro 7 Correlated with effector memory T-cell differentiation, known to provide immediate protection with limited long-term persistence in vitro 8 Serious Infections (continued): Prior to KYMRIAH infusion, infection prophylaxis should follow local guidelines. Monitor patients for signs and symptoms of infection after treatment with KYMRIAH and treat appropriately. Febrile neutropenia (grade 3 or 4) was also observed in 37% of patients after KYMRIAH infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad spectrum antibiotics, fluids, and other supportive care as medically indicated.
10 THE NOVARTIS COMMITMENT TO PATIENTS As a reminder of our commitment to patients and their families in need of KYMRIAH (tisagenlecleucel) CAR-T cell therapy, we have positioned the Wall of Hope in the main thoroughfare of our manufacturing facility. It lights up every time a patient s T cells are reprogrammed into KYMRIAH CAR-T cells. Serious Infections (continued): Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with drugs directed against B cells. HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously HBsAg negative and anti-hbc positive. Reactivation of HBV replication is often followed by hepatitis. Perform screening for HBV, HCV and HIV in accordance with clinical guidelines before cell collection for manufacturing.
11 KYMRIAH CARES is dedicated to providing personalized support throughout the KYMRIAH (tisagenlecleucel) treatment journey. Call KYMRIAH CARES at KYMRIAH ( ) for information on KYMRIAH, treatment center locations, coverage support, and patient assistance. Prolonged Cytopenias: Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and KYMRIAH infusion. Grades 3 and 4 cytopenias not resolved by Day 28 following KYMRIAH treatment included neutropenia (40%) and thrombocytopenia (27%) among 52 responding patients. At 56 days following KYMRIAH, 17% and 12% of responding patients had grades 3 and 4 neutropenia or thrombocytopenia respectively. Prolonged neutropenia has been associated with increased risk of infection. Myeloid growth factors, particularly GM-CSF, are not recommended during the first 3 weeks after KYMRIAH infusion or until CRS has resolved.
12 INDICATION KYMRIAH (tisagenlecleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. IMPORTANT SAFETY INFORMATION FOR KYMRIAH WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL TOXICITIES Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab. Neurological toxicities, which may be severe or life-threatening, can occur following treatment with KYMRIAH, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIAH. Provide supportive care as needed. KYMRIAH is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS. Contraindications None Warnings and Precautions Cytokine Release Syndrome: CRS, including fatal or life-threatening reactions, occurred following treatment with KYMRIAH. In Study 1, CRS occurred in 79% (54/68) of patients receiving KYMRIAH, including grade 3 or 4 (Penn grading system) CRS in 49% (33/68) of patients. The median time to onset of CRS was 3 days (range: 1-22 days). Of the 54 patients with CRS, 27 (50%) received tocilizumab; 7 (13%) patients received 2 doses of tocilizumab, 3 (6%) patients received 3 doses of tocilizumab and 14 (26%) patients received addition of corticosteroids (e.g. methylprednisolone). The median time to resolution of CRS was 8 days (range: 1-36 days). Key manifestations of CRS may include high fever, lower than normal blood pressure, difficulty breathing, and may be associated with hepatic, renal, and cardiac dysfunction, and coagulopathy. Risk factors for severe CRS are high pre-infusion tumor burden, uncontrolled or accelerating tumor burden following lymphodepleting chemotherapy, active infections, and/or inflammatory processes. Delay KYMRIAH infusion after lymphodepleting chemotherapy if patient has unresolved serious adverse reactions from preceding chemotherapies, active uncontrolled infection, active graft vs host disease, or worsening of leukemia burden. Ensure tocilizumab is available on-site prior to KYMRIAH infusion. Monitor patients for signs or symptoms of CRS for at least 4 weeks after treatment. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur. At the first sign of CRS, immediately evaluate the patient for hospitalization and institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated. Please see additional Important Safety Information on next pages.
13 IMPORTANT SAFETY INFORMATION FOR KYMRIAH (continued) Neurological Toxicities: Neurological toxicities, which may be severe or life-threatening, can occur following treatment with KYMRIAH (tisagenlecleucel). The majority of neurological toxicities occurred within 8 weeks following KYMRIAH infusion. In Study 1, neurological toxicities within 8 weeks after KYMRIAH infusion occurred in 65% of patients, including grade 3 or 4 neurological toxicities in 18% of patients, and 75% of events resolved within 12 days. The most common neurological toxicities were headache (37%), encephalopathy (34%), delirium (21%), anxiety (13%), and tremor (9%). Other manifestations of neurological toxicities included disturbances in consciousness, disorientation, confusion, agitation, seizures, mutism and aphasia. Monitor patients for neurological events and exclude other causes for symptoms. Provide supportive care as needed for KYMRIAH-associated neurological events. KYMRIAH REMS to Mitigate Cytokine Release Syndrome and Neurological Toxicities: Because of the risk of CRS and neurological toxicities, KYMRIAH is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS. Further information is available at or KYMRIAH ( ). Hypersensitivity Reactions: Allergic reactions may occur with KYMRIAH. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide or dextran 40 in KYMRIAH. Serious Infections: Serious infections, including life-threatening or fatal infections, occurred in patients after KYMRIAH infusion. In Study 1, infections (all grades) after KYMRIAH infusion occurred in 40 patients (59%), including 24 patients (35%) with grade 3 and 4 infections and 2 patients (3%) with fatal infections. Infections with an unknown pathogen occurred in 41% of patients, viral infections in 26%, bacterial infections in 19%, and fungal infections in 13%. Prior to KYMRIAH infusion, infection prophylaxis should follow local guidelines. Monitor patients for signs and symptoms of infection after treatment with KYMRIAH and treat appropriately. Febrile neutropenia (grade 3 or 4) was also observed in 37% of patients after KYMRIAH infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad spectrum antibiotics, fluids, and other supportive care as medically indicated. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with drugs directed against B cells. HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously HBsAg negative and anti-hbc positive. Reactivation of HBV replication is often followed by hepatitis. Perform screening for HBV, HCV and HIV in accordance with clinical guidelines before cell collection for manufacturing. Prolonged Cytopenias: Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and KYMRIAH infusion. Grades 3 and 4 cytopenias not resolved by Day 28 following KYMRIAH treatment included neutropenia (40%) and thrombocytopenia (27%) among 52 responding patients. At 56 days following KYMRIAH, 17% and 12% of responding patients had grades 3 and 4 neutropenia or thrombocytopenia respectively. Prolonged neutropenia has been associated with increased risk of infection. Myeloid growth factors, particularly GM-CSF, are not recommended during the first 3 weeks after KYMRIAH infusion or until CRS has resolved. Please see additional Important Safety Information on next page.
14 IMPORTANT SAFETY INFORMATION FOR KYMRIAH (continued) Hypogammaglobulinemia: Hypogammaglobulinemia and agammaglobulinemia (IgG) can occur in patients with a complete remission after KYMRIAH (tisagenlecleucel) infusion. In Study 1, 43% of patients had hypogammaglobulinemia. B-cell aplasia is an on-target effect of KYMRIAH and therefore a patient may experience hypogammaglobulinemia for as long as KYMRIAH persists. Monitor immunoglobulin levels after treatment with KYMRIAH and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement standard guidelines. The safety of immunization with live viral vaccines during or following KYMRIAH treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of lymphodepleting chemotherapy, during KYMRIAH treatment, and until immune recovery following treatment with KYMRIAH. Pregnant women who have received KYMRIAH may have hypogammaglobulinemia. Assess immunoglobulin levels in newborns of mothers treated with KYMRIAH. Secondary Malignancies: Patients treated with KYMRIAH may develop secondary malignancies or recurrence of their leukemia. Monitor life-long for secondary malignancies. If a second malignancy occurs, call KYMRIAH ( ) to obtain instructions on patient samples to collect for testing. Effects on Ability to Drive and Use Machines: Due to the potential for neurological events, patients receiving KYMRIAH are at risk for altered or decreased consciousness or coordination in the 8 weeks following infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities during this initial period. Drug Interactions HIV and the lentivirus used to make KYMRIAH have limited short spans of identical genetic material (RNA). Therefore, some commercial HIV nucleic acid tests (NATs) may yield false positive results in patients who have received KYMRIAH. Pregnancy, Lactation, Females and Males of Reproductive Potential There are no available data of KYMRIAH use in pregnant or lactating women. Therefore, KYMRIAH is not recommended for women who are pregnant or breastfeeding. Pregnancy after KYMRIAH administration should be discussed with the treating physician. Pregnancy status of females of reproductive potential should be verified with a pregnancy test prior to starting treatment with KYMRIAH. Report pregnancies to Novartis Pharmaceuticals Corporation at Adverse Reactions The most common adverse reactions (incidence greater than 20%) are cytokine release syndrome, hypogammaglobulinemia, infections-pathogen unspecified, pyrexia, decreased appetite, headache, encephalopathy, bleeding, hypotension, tachycardia, nausea, diarrhea, vomiting, viral infection disorders, hypoxia, fatigue, acute kidney injury, and delirium.
15 To learn more about KYMRIAH (tisagenlecleucel), please visit KYMRIAH-hcp.com. References: 1. Shu Z, Heimfeld S, Huang Z, Liu C, Gao D. Progress in cryopreservation of stem cells and immune cells for cytotherapy. In: Demirer T, ed. Progress in Stem Cell Transplantation. Rijeka, Croatia: InTechOpen; 2015: Wang SY, Hsu ML, Tzeng CH, Hsu HC, Ho CK. The influence of cryopreservation on cytokine production by human T lymphocytes. Cryobiology. 1998;37(1): Sadeghi A, Ullenhag G, Wagenius G, Tötterman TH, Eriksson F. Rapid expansion of T cells: effects of culture and cryopreservation and importance of short-term cell recovery. Acta Oncol. 2013;52(5): Thierry C, Turc JM, Valles H, Serrou B. Routine technique of lymphocyte cryopreservation evaluated by in vitro tests of immune response. Eur J Cancer. 1977;13(4-5): Data on file. Novartis CTL019 Leukapheresis Reference Manual: Leukapheresis Collection. Novartis Pharmaceuticals Corporation; Dec Kymriah [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8): Kawalekar OU, O Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2): Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi: /scitranslmed Please see Important Safety Information throughout. Please see full Prescribing Information for KYMRIAH, including Novartis Pharmaceuticals Corporation East Hanover, New Jersey Novartis 3/18 KYM
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationWhat should I ask my treatment team?
TREATMENT TRANSFORMED Child portrayed is not a real KYMRIAH patient. DISCUSSION GUIDE What should I ask my treatment team? Making treatment decisions for relapsed or refractory cancer can be hard. Asking
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationEngineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL
Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL Diana Schreier, Pharm.D., M.B.A. Pharmacy Grand Rounds October 17, 2017 2017 MFMER
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYMRIAH safely and effectively. See full prescribing information for KYMRIAH. KYMRIAH (tisagenlecleucel)
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More information-- Manufacturing Success Rate of 99 Percent in ZUMA-1 Pivotal Trial with a Median 17 Day Turnaround Time --
Kite s Yescarta (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of
More informationCAR- Your guide to KYMRIAH therapy. Transform your T cells for a transformed tomorrow. The first FDA-approved TREATMENT TRANSFORMED
TREATMENT TRANSFORMED The first FDA-approved CAR- Transform your T cells for a transformed tomorrow Your guide to KYMRIAH therapy Children portrayed throughout are not real KYMRIAH patients. IMPORTANT
More informationREMS Program Live Training FOR TRAINING PURPOSES ONLY
REMS Program Live Training FOR TRAINING PURPOSES ONLY This educational module contains information on selected YESCARTA -associated adverse reactions, including cytokine release syndrome and neurologic
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationNeedyMeds
NeedyMeds www.needymeds.org Find help with the cost of medicine Thank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need.
More informationDosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA Indications ARZERRA (ofatumumab) is indicated: In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic
More informationDosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL)
More informationA Guide for Patients and Caregivers
DLBCL Starting KYMRIAH A Guide for Patients and Caregivers APPROVED USE WHAT IS KYMRIAH? KYMRIAH (tisagenlecleucel) is made from your own white blood cells and is a prescription cancer treatment used in
More informationCAR T-Cell Therapy for Your Patients: What You Need To Know
CAR T-Cell Therapy for Your Patients: What You Need To Know Marco L. Davila, MD, PhD Associate Member, Blood & Marrow Transplantation and Cellular Immunotherapy Medical Director Cell Therapy Facility H.
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationYESCARTA (axicabtagene ciloleucel) suspension for intravenous infusion Initial U.S. Approval: October 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YESCARTA safely and effectively. See full prescribing information for YESCARTA. YESCARTA (axicabtagene
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationApplying Chimeric Antigen Receptor T cells (CAR-T) to hematologic malignancies
Applying Chimeric Antigen Receptor T cells (CAR-T) to hematologic malignancies Anne W. Beaven, MD Associate Professor Duke University Medical Center Duke Debates April 21, 2017 Chimeric Antigen Receptor
More informationoffers the possibility of a longer life 1 BLINCYTO A guide for patients and caregivers
In a study of 405 adults with Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, 271 were treated with BLINCYTO and 134 with chemotherapy. The adults
More informationWhat You Need to Know About ARZERRA (ofatumumab)
Starting your treatment for chronic lymphocytic leukemia (CLL) What You Need to Know About ARZERRA (ofatumumab) Approved Use ARZERRA is a prescription medication used: With a chemotherapy drug called chlorambucil
More informationCytokine Release Syndrome and Neurotoxicity
Cytokine Release Syndrome and Neurotoxicity Colette Chaney, RN,BSN,OCN Clinical Research Operations Manager Clinical Research Nurse Objectives Describe signs and symptoms of cytokine release syndrome and
More informationCAR T CELL IMMUNOTHERAPY FOR ALL. Stephan Grupp, MD, PhD
CAR T CELL IMMUNOTHERAPY FOR ALL Stephan Grupp, MD, PhD Disclosures Research and/or clinical trial support from Novartis, Servier, Vertex and Kite Study steering committees, consulting, or scientific advisory
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationwas proven to help people live longer1 BLINCYTO A guide for patients and caregivers
In a clinical trial for people with a certain kind of ALL whose cancer has returned or didn t respond to treatment 1 BLINCYTO was proven to help people live longer1 In a study of 405 adults with ALL, 271
More informationYescarta (axicabtagene ciloleucel)
Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More informationBLINCYTO can eliminate detectable traces of cancer 1
For people* with B-cell precursor ALL who are MRD+, 1 BLINCYTO can eliminate detectable traces of cancer 1 In a study of 86 adults with MRD+ B-cell precursor ALL, BLINCYTO removed detectable traces of
More informationExploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies
Exploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies Maurice Alexander, PharmD, BCOP, CPP Clinical Specialist, Blood and Marrow Transplant UNC Bone Marrow
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationCAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes Shannon L. Maude, MD, PhD CTL019 cell Lentiviral vector Anti-CD19 CAR construct CD19 Native
More informationIntroduction. Summary A LOOK AT CAR-T THERAPIES MARCH 2018 LEUKEMIA AND LYMPHOMA CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY
MARCH 2018 Introduction LEUKEMIA AND LYMPHOMA This review focuses on two types of B-cell cancers: childhood B-cell acute lymphoblastic leukemia (B-ALL), and aggressive B-cell non-hodgkin s lymphoma (NHL)
More informationIMMUNE EFFECTOR CELLS: CAR T AND OTHER CYTOTOXIC EFFECTOR CELLS OF THE IMMUNE SYSTEM
IMMUNE EFFECTOR CELLS: CAR T AND OTHER CYTOTOXIC EFFECTOR CELLS OF THE IMMUNE SYSTEM Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies
More informationImportant new concerns or changes to the current ones will be included in updates of YESCARTA s RMP.
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for YESCARTA (axicabtagene ciloleucel) This is a summary of the risk management plan (RMP) for YESCARTA. The RMP details important
More informationGAZYVA Dosing and Administration Guide
GAZYVA Dosing and Administration Guide Indications GAZYVA is a CD20-directed cytolytic antibody and is indicated: In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at
More informationExample Clinician Educational Material for Providers of Immune Effector Cellular Therapy
Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy Disclaimer: This example is just one of many potential examples of clinician education material that can be provided
More informationHave a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider
Have a healthy discussion Use this guide to start a conversation with your healthcare provider MAKE THE CONVERSATION COUNT Here are some things you may want to reflect on and discuss with your healthcare
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationTalking about your treatment. A guide to the conversations you may have before starting LEMTRADA
Talking about your treatment A guide to the conversations you may have before starting LEMTRADA INTRODUCTION HEALTHCARE TEAM CARE TEAM COWORKERS Please see Important Safety Information on pages 6-7 and
More informationChimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma
Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma Stephen J. Schuster, M.D. Director, Lymphoma Program & Lymphoma Translational Research, Abramson Cancer
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More information4100: Cellular Therapy Essential Data Follow-Up Form
4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:
More informationImmunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy
Immunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy This transcript has been edited for style and clarity and includes all slides from the presentation. This
More informationAn Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib)
An Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib) IMBRUVICA (ibrutinib) is a meaningful and important treatment option for patients with chronic lymphocytic
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationGAZYVA for Chronic Lymphocytic Leukemia (CLL)
GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous
More informationBilling & Coding Guide
Billing & Coding Guide CMS established a unique J-code to facilitate reimbursement of ENVARSUS XR J7503 Suggested Coding and Medicare Allowables Coding Overview and Payment Rates Used to Report Code Description
More informationChimeric Antigen Receptors (CAR)
CAR Therapy In CLL Chimeric Antigen Receptors (CAR) 4-1BB (CD137) Costimulatory Domains: 0 1 2 PENN: 4-1BB MSKCC: CD28 USCD: CD28 Porter, D.L. et al Sci Trans Med 7:1-12, 2015 CD19 CAR T Cell Therapy For
More informationLEMTRADA REMS Education Program for Healthcare Facilities
For Healthcare Facilities LEMTRADA REMS Education Program for Healthcare Facilities This Educational Piece Includes Information About: The LEMTRADA REMS Program requirements to implement in your healthcare
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Supportive Care for NHL Tumor Lysis Syndrome (TLS) Laboratory hallmarks of TLS:
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN
More informationGAZYVA: for follicular lymphoma that has not responded to or has returned after treatment
GAZYVA: for follicular lymphoma that has not responded to or has returned after treatment GAZYVA is a prescription medicine used with the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More information(212) (347)
EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer
More informationGAZYVA for Chronic Lymphocytic Leukemia (CLL)
GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous
More informationChimeric Antigen Receptor - CAR T cell therapy. Frederick L. Locke, MD 2/17/2017
Chimeric Antigen Receptor - CAR T cell therapy Frederick L. Locke, MD 2/17/2017 T cells are immune system cells that normally fight infection Each T cell recognizes a specific target T cells multiply and
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationSwiss Summary of the Risk Management Plan (RMP) for BLINCYTO (Blinatumomab)
Swiss Summary of the Risk Management Plan (RMP) for BLINCYTO (Blinatumomab) RMP Summary: Version 1, April 2017 EU RMP: Version 3.2, November 2016 Page 1 of 13 The Risk Management Plan (RMP) is a comprehensive
More informationRiTUXimab 375 mg/m 2 Therapy-7 day
RiTUXimab 375 mg/m 2 Therapy-7 day This regimen supercedes NCCP Regimen 00208 rituximab 375mg/m2 therapy-follicular lymphoma as of February 2019 INDICATIONS FOR USE: Regimen *Reimbursement INDICATION ICD10
More informationNCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy
Brentuximab INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell
More informationAntiemetic protocol for rare emetogenic chemotherapy - see protocol SCNAUSEA
BCCA Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with obinutuzumab and Chlorambucil Protocol Code Tumour Group Contact Physician
More informationSUMMARY OF THE RISK MANAGEMENT PLAN FOR. BESPONSA 1mg (INOTUZUMAB OZOGAMICIN) Powder for concentrate for solution for infusion.
SUMMARY OF THE RISK MANAGEMENT PLAN FOR BESPONSA 1mg (INOTUZUMAB OZOGAMICIN) Powder for concentrate for solution for infusion. This RMP Summary is based on Part VI of the EU RMP for BESPONSA (Inotuzumab
More informationThe only biologic approved to treat SLE: now with multiple delivery options
The only biologic approved to treat SLE: now with multiple delivery options BENLYSTA (belimumab) Autoinjector SC Prefilled syringe IV Intravenous infusion Consider the options: visit Belimumab.com INDICATION
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)
More informationHuman plasma protein 50 mg/ml of which at least 96% is IgG, with a content of antibodies to Hepatitis B virus surface antigen (HBs) of 50 IU/ml
Hepatect CP 1. NAME OF THE MEDICINAL PRODUCT Hepatect CP 50 IU/ml; solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. Human plasma protein 50 mg/ml of which
More informationNCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy
INDICATIONS FOR USE: Obinutuzumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities
More informationHuman Herpes Virus-6 Limbic Encephalitis
Case Studies [1] March 19, 2013 Case history: A 32-year-old Caucasian female with newly diagnosed acute myeloid leukemia (AML) was treated with induction chemotherapy and attained complete remission. She
More informationOF HIS TREATMENT FOR RELAPSED MULTIPLE MYELOMA. Understanding the steps on your treatment journey
EMMETT TAKES CHARGE OF HIS TREATMENT FOR RELAPSED MULTIPLE MYELOMA Understanding the steps on your treatment journey APPROVED USE KYPROLIS (carfilzomib) is a prescription medication used to treat patients
More informationPneumococcal 13-valent Conjugate Vaccine Biological Page
Pneumococcal 13-valent Conjugate Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.291 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Human proteins g/l g/l of which human immunoglobulin at least to. 180 IU/ml 180 IU/vial
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT UMAN BIG 180 IU/ml Solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. UMAN BIG 180 IU/1
More informationCAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris
CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION
More informationAdoptive Immunotherapy
Adoptive Immunotherapy Policy Number: 8.01.01 Last Review: 10/2018 Origination: 12/2015 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Adoptive
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationFuel your determination to live longer with KYPROLIS. Look inside to learn more.
F O R R E L A P S E D MULT IP L E M Y E L OM A APPROVED USES KYPROLIS is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Human Medicines Evaluation Unit London, 27 April 2006 CPMP/BPWG/4027/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CORE SPC FOR HUMAN PLASMA DERIVED
More informationOlive J Sturtevant, MHP, MT(ASCP)SBB/SLS, CQA Director, Cellular Therapy Quality Assurance Dana Farber Cancer Institute
Adverse Events associated with Cell Therapy Products Olive J Sturtevant, MHP, MT(ASCP)SBB/SLS, CQA Director, Cellular Therapy Quality Assurance Dana Farber Cancer Institute 2 Objectives Review the types
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More informationKymriah (tisagenlecleucel)
Kymriah (tisagenlecleucel) Policy Number: Original Effective Date: MM.02.036 06/01/2018 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2018 Section: Medicine Place(s) of Service:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationSummary of the risk management plan (RMP) for Kyprolis (carfilzomib)
EMA/639793/2015 Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) This is a summary of the risk management plan (RMP) for Kyprolis, which details the measures to be taken in order to
More informationCSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1
Page 1 CSL Behring Albuminar -25 Albumin (Human) USP, 25% R x only DESCRIPTION Albuminar -25, Albumin (Human) 25%, is a sterile aqueous solution of albumin obtained from large pools of adult human venous
More informationAdoptive Immunotherapy
Adoptive Immunotherapy Policy Number: 8.01.01 Last Review: 6/2018 Origination: 12/2015 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Adoptive
More informationIVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,
More information